OBJECTIVE： To explore the general regulation and characteristics of adverse drug reactions （ADR） induced by ticagrelor， and provide reference for clinical rational drug use. METHODS： 672 patients received ticagrelor in our hospital from Dec. 2013 to Jun. 2015 were followed-up， and the situation was analyzed and summarized after taking drug. RESULTS： In the 672 patients， 78 （11.6％） patients sutfered from 108 cases of ADR， the ratio of male to female was 5.5 ∶ 1， there was statistical significance （P＜0.05）； patients mostly aged 51-60 years （37.2％）； the mainly involved organs/systems were respiratory system （41.7％）， and skin and its appendages （38.0％）， the main clinical manifestations were minor bleeding （78.7％）， dyspnea （17.6％） and bradycardia （2.8％）；no severe ADR was found. CONCLUSIONS： Ticagrelor had good safety and tolerability， but due to its shorter time to market in China and absense of evidence-based medicine for large-scale clinical trials in Asian population， clinic should strengthen medication monitoring to reduce the ADR and ensure drug safety.